ResMed Inc. stock falls after valuation warning but fundamentals stay solid

ResMed Inc. stock (ISIN US7611521078) is trading near USD 221 in early trading on September 9, 2026, after closing at USD 221.05 on September 8, 2026, marking a 3.2 percent decline that pushed the shares further away from their 52-week high of USD 284.87.

Stock under pressure despite growth

According to GuruFocus on September 8, 2026, ResMed shares fell 3.2 percent to a closing price of USD 221.05, leaving the stock down 7.5 percent year-to-date and 20.1 percent over the past twelve months.

The same analysis from GuruFocus highlights that ResMed's current market price of USD 221.05 is 17.3 percent below its calculated GF Value of USD 267.39, suggesting that the stock may be undervalued relative to the platform's intrinsic value estimate.

Fundamentals show continued expansion

ResMed has delivered consistent growth in recent reporting periods, with double-digit increases in revenue and earnings per share over its most recent fiscal year and latest quarter, providing a fundamental backdrop for the valuation discussion.

In its latest reported quarter within the last nine months, the company increased revenue by a mid-teens percent rate compared with the prior-year period, while net income and earnings per share also grew at a double-digit pace over the same timeframe, reflecting operational leverage in its core sleep apnea and respiratory care business.

Market view and investor takeaways

With the shares trading at USD 221.05 as of the close on September 8, 2026, roughly one fifth below the 52-week high of USD 284.87, ResMed Inc. stock offers investors a combination of recent price weakness and ongoing fundamental expansion that frames the current debate around valuation and future returns.

More news and analyses on ResMed Inc. stock